QbD Costs Less
This article was originally published in The Gold Sheet
At the Sept. 24 joint PDA/FDA regulatory workshop discussion on the ICH Q8 guideline in Washington, which introduces the concept of design space, Moheb Nasr, director of the Office of New Drug Quality Assessment at CDER, said that "the more you understand [the drug product] at small-scale, the less you have to do at the commercial operation….I think you wind up reducing the costs in the long-run. The cost of QbD is much less than what people think." Nasr added that manufacturers who are confused about what to submit "when you're in the IND process for Phase 2, have a dialogue with the agency. We can provide free advice to you.
You may also be interested in...
Medtech Insight spoke to attorney Greg Dadika about mass tort litigation, including industry trends, how to find the right law firm, and when it’s the right time to settle a suit. See what Dadika, an attorney at the law firm Greenberg Traurig LLP, said about it here.
AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.
Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.